

## Abstract Submission - General Guidelines and Regulations

### Call for Abstracts and Abstract Submission Guidelines

The Organising Committee welcomes the submission of original contributions for abstracts at DHM 2026.

**DEADLINE: Thursday, 8 JANUARY 2026, at 23:59 CET**

EAACI does not charge any fee for abstract submission. Abstracts can only be submitted on the online platform on the event website. Abstracts submitted via email, post or fax will not be accepted.

## 1. General information

### 1.1 Instructions to authors

Carefully read the guidelines below before submitting your abstract:

Abstracts not adhering to DHM 2026 Abstract Submission – General Guidelines and Regulations will be rejected. The final decision about acceptance of an abstract will be taken by the DHM Scientific Programme Committee. EAACI does not communicate, nor enter into correspondence on the reason for acceptance or rejection of an abstract.

Upon submission, a confirmation email will be sent to the submitters email address. If you do not receive the confirmation e-mail, please do not submit the abstract again. Instead, please contact the Scientific Secretariat [abstract@eaaci.org](mailto:abstract@eaaci.org) for advice.

### 1.2 Declaration of conflict of interest

EAACI is committed to ensuring the integrity of scientific, educational, and research programmes. Abstract submission requires disclosure of any financial or other interest that might be construed as resulting in an actual, potential, or apparent conflict. The submitter is responsible for obtaining disclosure information from all co-authors, to be entered in the author section of the submission page.

## 2. Submission guidelines

### 2.1 Technical requirements

#### 2.1.1 Personal Page

When entering the abstract submission system for the first time, you will be asked to create a MyEAACI account (if you don't have one already). Through your MyEAACI account you will be able to access your personal page to submit one or several abstracts. You can edit your abstracts until the submission deadline on **THURSDAY 8 JANUARY 2026 at 23:59 CET**.

#### 2.1.2 Abstract language and length

Abstracts and presentations must be written in **English**. The maximum length allowed for an abstract is 2500 characters (approximately 350 words) including blank spaces. The abstract title, the author(s) or names of institutions are not included in the count of 2500 characters.

#### 2.1.3 Tables and Figures

If appropriate one table and/or one figure (charts, diagrams and statistical overviews uploaded as a picture) are allowed. Please do not upload any kind of patient pictures.

#### **2.1.4 Abstract structure and content**

You are allowed to be the presenting author of more than one abstract, three (3) is the maximum number of abstracts that can be presented by the same author. You are allowed to be a co-author of an unlimited number of abstracts. Submission of closely related abstracts from the same group is discouraged.

To make the abstract as informative as possible, we require a brief statement of the purpose of the study and/or the underlying hypotheses (background), the method used, the results observed, and the conclusions based upon the results. Abstracts without results will be rejected. It is inadequate to state "The results will be discussed" or "The data will be presented".

#### **2.1.5 Duplication of publications**

Abstracts will only be considered for presentation if they are not published or submitted for presentation elsewhere.

### **2.2 Abstract presentation**

#### **2.2.1 Presentation formats and abstract topics**

Accepted abstracts selected by expert reviewers will be presented in any of the following sessions: Oral Abstract Sessions (OAS) and Poster Session (TPS).

**OAS and TPS formats will be presented in Antwerp only. No electronic presentation format is foreseen.**

For clinical studies, clinical trials or translational research abstract submissions, the presenting author can be any of the listed authors, but without affiliations to industry.

For basic research abstract submissions, the presenting author can be any of the listed authors.

#### **2.2.2 Oral Abstract Session**

The Oral Abstract Sessions (OAS) consist of oral presentations followed by discussion. As presenter, you are required to prepare a MS PowerPoint presentation featuring the main findings of your work. An email with detailed information will be sent to the presenting author in due course.

#### **2.2.3 Poster Session**

The Poster Session (TPS) will allow for the presentation of your work during the Poster sessions. Each Poster Session will allow poster presenters to interact with participants for 90 minutes by standing next to their poster.

### **2.3 Abstract instructions**

#### **2.3.1 Notification of acceptance**

Notifications of acceptance or rejection of the abstracts will be sent to the presenting author of the abstract by the **mid-February 2026**.

The submitting author will receive the confirmation email stating that the abstract has been submitted successfully. All further communication including the notification letter will be **ONLY** with the presenting author that has been indicated during the abstract submission.

With the notification of acceptance, abstract presenters will be informed about the format.

The presenting author must be registered using the same email address which was used for the abstract submission. This is to ensure that the abstract and registration can be matched. **If the presenting author is not registered by 26 February 2026** and/or the email addresses used do not match, the abstract will not be published in the congress programme.

### **2.3.2 Registration**

The presenting author of an abstract must register for the event. Until **26 February 2026**, the presenting author is offered a special extended “early fee”. The registration fee may be refunded if the abstract is rejected. Please note that some countries require a visa to visit Portugal.

### **2.3.3 Publication of abstracts**

Accepted abstracts will be published in the online programme and EAACI website during the event. In order to have your abstract published on the website you need to be registered for the event by the given deadline.

### **2.3.4 No-show policy**

Submission of an abstract constitutes a formal commitment by the author(s) to present the work if accepted. If a presenting author of an accepted abstract does not register for the event until the deadline, or does not show up to their allocated presentation, he/she risks jeopardizing future acceptance at other EAACI Congresses and Events, if not justified (withdrawn). These abstracts will be excluded from publication on the EAACI website.

### **2.3.5 Withdrawal of an abstract**

If you need to withdraw your abstract, a written statement listing the reasons for this decision must be sent to [abstract@eaaci.org](mailto:abstract@eaaci.org) by **3 March 2026** (withdrawals after the given deadline cannot be accepted).

### **2.3.6 Abstract Embargo**

Accepted abstracts are made available to the public on the Event website on the first day of DHM 2026 event at 09:00 CET.

Hence, the embargo is lifted at 09:00 hrs CET on the starting day of DHM 2026 and can be reported from that time onwards.

Abstracts accepted for the event are subject to the [EAACI embargo rules](#) as published on the EAACI Website.

### **2.3.7 Copyright**

By submitting your abstract to the DHM 2026 you are agreeing to the transfer of the copyright to EAACI. The submission of abstracts accepted for DHM 2026 requires the permission of EAACI as copyright holder.

### **2.3.8 Data Privacy**

By certifying that you have read these submission rules, you also confirm having received the prior approval from the co-authors to provide their data to the DHM 2026.

The information collected in this call for abstract submission is subject to data processing to proceed with the elaboration of the Scientific Programme during the DHM 2026.

Provision of personal data is a statutory requirement to list the authors who have contributed to research submitted. Authors not listed in the submission will not be acknowledged in the abstract

Your personal data will be shared with EAACI, CYIM, the EAACI Committees, and abstract reviewers involved in the abstract selection for the DHM 2026. Transfer of personal data to contractors as well as EAACI related scientific organizations may occur for production, promotion and dissemination of congress content.

In accordance with the chapter 3 of the European Regulation 2016/679 with regards to data protection, you have the right to request EAACI access, rectification or erasure of your personal data, restriction or object to processing as well as the right to data portability. This is one through withdrawal of the abstract according to the terms and conditions of withdrawal. For such, please contact (together with a proof of identity):

Data Privacy

European Academy of Allergy and Clinical Immunology (EAACI)  
Hagenholzstrasse 111  
CH-8050 Zurich  
Or by email to: [gdpr@eaaci.org](mailto:gdpr@eaaci.org)

### **2.3.9 Abstract Review**

All abstracts will be blinded for review by a minimum of 3 members of the abstract review committee. All the reviewers have been selected by the Organising Committee to review abstracts in their category that best fit their expertise. EAACI aims for good quality of science without compromising scientific integrity.

The abstract reviewers are required to identify abstracts pertaining to the commercial promotion of a proprietary product or data originating from the same study across several abstracts in order to notify the Organising Committee for further action.

**Please note that the final decisions regarding acceptance of the submitted abstract will be made by the Organising Committee. No rescheduling or changes by the submitters will be possible once the abstract deadline is closed.**

#### **Contact**

For any assistance for the submission of the abstract, please contact the Scientific Secretariat at: [abstract@eaaci.org](mailto:abstract@eaaci.org)

**Please read our privacy notice on our website to understand how we process your personal data and what rights you have.**

*Deadlines are subject to change.*

Date: September 2025